Functionalized Congener Approach to Muscarinic Antagonists: Analogues of Pirenzepine

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 1991 Jul 1

PMID 2066986

Citations 7

Authors

Y Karton

B J Bradbury

J BAUMGOLD

R Paek

K A Jacobson

Affiliations

Soon will be listed here.

Abstract

The M1-selective muscarinic receptor antagonist pirenzepine 6H-pyrido[2,3-b][1,4]benzodiazepin-6-one) was derivatized to explore points of attachment of functionalized side chains for the synthesis of receptor probes and ligands for affinity chromatography. The analogues prepared were evaluated in competitive binding assays versus [3H]-N-methylscopolamine at four muscarinic receptor subtypes (m1AChR-m4AChR) in membranes from rat heart tissue and transfected A9L cells. 9-(Hydroxymethyl)pirenzepine, 8-(methylthio)pirenzepine, and a series of 8-aminosulfonyl derivatives were synthesized. Several 5-substituted analogues of pirenzepine also were prepared. An alternate series of analogues substituted on the 4-position of the piperazine ring was prepared by reaction of 4-desmethylpirenzepine with various electrophiles. An N-chloroethyl analogue of pirenzepine was shown to form a reactive aziridine species in aqueous buffer yet failed to affinity label muscarinic receptors. Within a series of aminoalkyl analogues, the affinity increased as the length of the alkyl chain increased. Shorter chain analogues were generally much less potent than pirenzepine, and longer analogues (7-10 carbons) were roughly as potent as pirenzepine at m1 receptors, but were nonselective. Depending on the methylene chain length, acylation or alkyl substitution of the terminal amine also influenced the affinity at muscarinic receptors.

Citing Articles

MUSCARINIC RECEPTOR PROBES BASED ON AMINE CONGENERS OF PIRENZEPINE AND TELENZEPINE.

Jacobsont K, Kartont Y, Baumgold J Bioorg Med Chem Lett. 2024; 2(8):845-850.

PMID: 38213641 PMC: 10782887. DOI: 10.1016/s0960-894x(00)80542-9.

Unexpected scaffold rearrangement product of pirenzepine found in commercial samples.

Ozenil M, Skos L, Roller A, Gajic N, Holzer W, Spreitzer H Sci Rep. 2021; 11(1):23397.

PMID: 34862437 PMC: 8642400. DOI: 10.1038/s41598-021-02732-y.

Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Jacobson K Bioconjug Chem. 2009; 20(10):1816-35.

PMID: 19405524 PMC: 2888900. DOI: 10.1021/bc9000596.

Amphiphilic pyridinium salts block TNF alpha/NF kappa B signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells.

Tchilibon S, Zhang J, Yang Q, Eidelman O, Kim H, Caohuy H Biochem Pharmacol. 2005; 70(3):381-93.

PMID: 15963954 PMC: 8383153. DOI: 10.1016/j.bcp.2005.05.002.

Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists.

Jacobson K, Fischer B, Van Rhee A Life Sci. 1995; 56(11-12):823-30.

PMID: 10188781 PMC: 3561779. DOI: 10.1016/0024-3205(95)00016-y.

References

Bradbury B, BAUMGOLD J, Jacobson K . Functionalized congener approach for the design of novel muscarinic agents. Synthesis and pharmacological evaluation of N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl] amides. J Med Chem. 1990; 33(2):741-8. DOI: 10.1021/jm00164a044. View

Shai Y, Kirk K, Channing M, Dunn B, Lesniak M, Eastman R . 18F-labeled insulin: a prosthetic group methodology for incorporation of a positron emitter into peptides and proteins. Biochemistry. 1989; 28(11):4801-6. PMC: 3425638. DOI: 10.1021/bi00437a042. View

Bradbury B, BAUMGOLD J, Paek R, Kammula U, Zimmet J, Jacobson K . Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides. J Med Chem. 1991; 34(3):1073-9. DOI: 10.1021/jm00107a029. View

Hammer R, Berrie C, Birdsall N, BURGEN A, Hulme E . Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature. 1980; 283(5742):90-2. DOI: 10.1038/283090a0. View

Wheatley M, Hulme E, Birdsall N, Curtis C, Eveleigh P, Pedder E . Peptide mapping studies on muscarinic receptors: receptor structure and location of the ligand binding site. Trends Pharmacol Sci. 1988; Suppl:19-24. View

Melchiorre C, Minarini A, Angeli P, Giardina D, Gulini U, Quaglia W . Polymethylene tetraamines as muscarinic receptor probes. Trends Pharmacol Sci. 1989; Suppl:55-9. View

Martinez J, Bali J, Rodriguez M, Castro B, Magous R, Laur J . Synthesis and biological activities of some pseudo-peptide analogues of tetragastrin: the importance of the peptide backbone. J Med Chem. 1985; 28(12):1874-9. DOI: 10.1021/jm00150a020. View

Barone S, Churchill P, Jacobson K . Adenosine receptor prodrugs: towards kidney-selective dialkylxanthines. J Pharmacol Exp Ther. 1989; 250(1):79-85. PMC: 3476460. View

Yatani A, Hamm H, CODINA J, Mazzoni M, Birnbaumer L, Brown A . A monoclonal antibody to the alpha subunit of Gk blocks muscarinic activation of atrial K+ channels. Science. 1988; 241(4867):828-31. DOI: 10.1126/science.2457252. View

10.

Hait W, GLAZER L, Kaiser C, Cross J, Kennedy K . Pharmacological properties of fluphenazine-mustard, an irreversible calmodulin antagonist. Mol Pharmacol. 1987; 32(3):404-9. View

11.

Stiles G, Jacobson K . High affinity acylating antagonists for the A1 adenosine receptor: identification of binding subunit. Mol Pharmacol. 1988; 34(6):724-8. PMC: 3557832. View

12.

Olah M, Jacobson K, Stiles G . Purification and characterization of bovine cerebral cortex A1 adenosine receptor. Arch Biochem Biophys. 1990; 283(2):440-6. PMC: 3476062. DOI: 10.1016/0003-9861(90)90665-l. View

13.

Bonner T, Young A, Brann M, Buckley N . Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1988; 1(5):403-10. DOI: 10.1016/0896-6273(88)90190-0. View

14.

Newman A, Covington J, Oleshansky M, Jackson B, Weissman B, Leader H . Aprophit: an irreversible antagonist for muscarinic receptors. Biochem Pharmacol. 1990; 40(6):1357-64. DOI: 10.1016/0006-2952(90)90404-9. View

15.

Maeda A, Kubo T, Mishina M, Numa S . Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes. FEBS Lett. 1988; 239(2):339-42. DOI: 10.1016/0014-5793(88)80947-5. View

16.

Eberlein W, Engel W, Mihm G, Rudolf K, Wetzel B, Entzeroth M . Structure-activity relationships and pharmacological profile of selective tricyclic antimuscarinics. Trends Pharmacol Sci. 1989; Suppl:50-4. View

17.

Winkler J, Thermos K, Weiss B . Differential effects of fluphenazine-N-mustard, on calmodulin activity and on D1 and D2 dopaminergic responses. Psychopharmacology (Berl). 1987; 92(3):285-91. DOI: 10.1007/BF00210832. View

18.

Eberlein W, Trummlitz G, Engel W, Schmidt G, Pelzer H, Mayer N . Tricyclic compounds as selective antimuscarinics. 1. Structural requirements for selectivity toward the muscarinic acetylcholine receptor in a series of pirenzepine and imipramine analogues. J Med Chem. 1987; 30(8):1378-82. DOI: 10.1021/jm00391a019. View

19.

Melchiorre C, Cassinelli A, Quaglia W . Differential blockade of muscarinic receptor subtypes by polymethylene tetraamines. Novel class of selective antagonists of cardiac M-2 muscarinic receptors. J Med Chem. 1987; 30(1):201-4. DOI: 10.1021/jm00384a034. View

20.

Ringdahl B, Mellin C, Ehlert F, Roch M, Rice K, JENDEN D . Tertiary 2-haloethylamine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride. J Med Chem. 1990; 33(1):281-6. DOI: 10.1021/jm00163a046. View